-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: August 2011
Raising the Stakes in Biotech
Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >
When RARE is not so RARE!
By Nicole Boice, Founder/President, RARE Project Did you know that there is a community of sick and disabled women, children, and men that is so large that it outnumbers all of those with cancer and AIDS combined worldwide? Scary to think about? Can you guess what it is? Staggering Statistics The Rare Disease Community is made up of over 7,000 known rare diseases and over 350 million people worldwide. Here in the US, over 35 Read More >
State Legislator Profile: Washington State Rep. John McCoy
If you ask most people to name a few things about the state of Washington, the word technology is likely to wind up somewhere in the mix. However, the birthplace of Microsoft and Amazon.com is also a biotech heavyweight. Washington contains one of the world’s largest life sciences clusters and is home to dozens of research institutes and some of the nation’s leading public research universities. The biotech industry in Washington employs tens of thousands Read More >
BioCentury TV at BIO International Convention
BioCentury TV interviewed biotech leaders throughout the recent BIO International Convention in Washington, DC. The first interview can be found here (links to the other interviews can be found on the right). (July 24) Public+Private Part 1 — Turning Great Science into Medicine — and Jobs: Dr. Michel Goldman of Europe’s Innovative Medicines Initiative xplains how the pharma-driven agenda is creating a new “ecosystem” in Europe for drug developers. (July 31) Public+Private Part 2 – Read More >
Biotechnology Patenting in Europe Event
BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States. Most of this cost is mainly due to language translation requirements and renewal fees. Read More >
